Monopar Therapeutics (MNPR) Common Equity (2016 - 2020)
Monopar Therapeutics (MNPR) has disclosed Common Equity for 5 consecutive years, with $17.5 million as the latest value for Q3 2020.
- Quarterly Common Equity rose 278.2% to $17.5 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $17.5 million through Sep 2020, up 278.2% year-over-year, with the annual reading at $12.6 million for FY2019, 82.53% up from the prior year.
- Common Equity hit $17.5 million in Q3 2020 for Monopar Therapeutics, up from $12.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $17.5 million in Q3 2020 to a low of $2.8 million in Q4 2016.
- Historically, Common Equity has averaged $8.8 million across 5 years, with a median of $8.1 million in 2018.
- Biggest five-year swings in Common Equity: tumbled 38.95% in 2019 and later surged 278.2% in 2020.
- Year by year, Common Equity stood at $2.8 million in 2016, then surged by 239.78% to $9.6 million in 2017, then decreased by 28.08% to $6.9 million in 2018, then soared by 82.53% to $12.6 million in 2019, then surged by 38.52% to $17.5 million in 2020.
- Business Quant data shows Common Equity for MNPR at $17.5 million in Q3 2020, $12.2 million in Q2 2020, and $12.4 million in Q1 2020.